The South America Pancreatic Cancer globally, pancreatic cancer is the 12th most common cancer in men and 11th most common cancer in women. Addiction to cigarettes and health history are considered to be the foremost reasons increasing the risk.
Some factors contributing to the growth of the market are large number of unmet needs related to the disease, attracting many multi-national companies to invest in this division, increasing healthcare expenditure, technological developments & drug innovations with regard to the pancreatic cancer and growing concern across the world.
Some factors limiting the growth of the market are Difficulty in diagnosis during the early stages, limited treatment options, especially when the disease has spread to other organs or parts of the body, inadequate results after treatment, low success rates in clinical trials for cancer drugs and high cost associated with the treatment
The South American pancreatic cancer therapeutics & diagnostic market is segmented based on the type of cancer into endocrine and exocrine cancers. By the type of treatment, the market is segmented into surgery, chemotherapy, radiation therapy and targeted therapy. By the major tests, the market has been segmented into biopsy, endoscopic ultrasound, laparoscopy and CT scan ERCP. On the basis of geography, the market has been segmented into Argentina, Brazil and Rest of South America.
Some of the key players in this market include –
Amgen, Inc., Celgene Corporation, Clovis Oncology, Inc., Eli Lilly and Company, Novartis AG and Threshold Pharmaceuticals, Inc. are some of the major key players.
Market analysis for the market, with region specific assessments and competition analysis.
Market definition along with the identification of key drivers, restraints opportunities and challenges.
Identification of factors instrumental in changing the market scenario, rising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale.
Extensively researched competitive landscape section with company profiles of key players with the analysis of their current strategic interests and key financial information.
Identification and analysis of the macro and micro factors that affect the South America Pancreatic Cancer Market. Insights of the market in the regions that have the highest potential for growth and also identify the markets that are still untapped.
Related Topics South America Pancreatic Cancer Market Market - Growth, Trends and Forecasts (2017 - 2022)
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porters Five Forces
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threats of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities and Challenges Analysis (Droc)
6.1 Market Drivers
6.1.1 Large Number of Unmet Needs in the Disease
6.1.2 Increase in the Healthcare Expenditure
6.1.3 Increasing Concern across the Globe
6.2 Market Restraints
6.2.1 Inadequate Results after Treatment
6.2.2 Difficulties in Early Diagnosis
6.2.3 High Cost Associated with the Treatment
6.2.4 Low Success Rate in Clinical Trials for Cancer Drugs
6.4 Key Challenges
7. Market Segmentation
7.1 Segmentation by Cancer Type
7.1.1 Pancreatic Adenocarcinoma
7.1.2 Acinar Cell Carcinoma
7.1.5 Endocrine Cancers (PanNETs)
7.2 Segmentation by Treatment Type
7.2.3 Radiation Therapy
7.2.4 Chemoradiation Therapy
7.2.5 Targeted Therapy
7.3 Segmentation by Diagnostics
7.3.2 Confirmatory Needle biopsy
7.3.3 Endoscopic Ultrasound
7.3.5 CT Scan
7.3.6 PET Scan
7.4 Segmentation by region
7.4.1 South America
188.8.131.52 Rest of South America
8. Competitive Landscape
8.1 Mergers and Acquisition Analysis
8.2 Agreements, Collaborations & Partnerships
8.3 New Products Launches
9. Key Players
9.1 Amgen, Inc.
9.2 Eli Lilly and Company
9.3 Celgene Corporation
9.4 Clovis Oncology, Inc.
9.5 Novartis AG
9.6 Threshold Pharmaceuticals, Inc.
9.7 Incyte Corp
9.8 Merrimack Pharmaceuticals Inc.
9.9 Roche Ltd
9.10 NewLink Genetics
10. Future outlook of the market